Electricity (Rights of Consumers) Rules, 2020: Norms bring in compensation mechanism
This is because the provisions make distribution companies more accountable to consumers. December 23, 2020 3:02:59 am
Now, as per law, states will have to implement these rules and discoms will be held more accountable for issues like delays in providing and renewing connections of electricity.
The government on Monday notified the Electricity (Rights of Consumers) Rules, 2020. These rules serve to “empower” consumers with rights that would allow them to access continuous supply of quality, reliable electricity. This is because the provisions make distribution companies more accountable to consumers.
The rules cover 11 key areas of power supply to consumers in the country, including obligations of distribution licensees, metering arrangements, release of new connections and modifications of existing connections and grievance redressal and compensation mec
Electricity Rules: Timely connection, 24×7 supply; fines in place for discoms
According to the Ministry, the move was “necessary” because distribution companies, regardless of whether they are public or private, are “monopolies”, and the consumer has no alternative. December 22, 2020 3:00:54 am
Penalties to be credited to consumer’s account. (File)
The government on Monday notified rules that would allow consumers in India to access continuous supply of quality, reliable electricity. The Electricity (Rights of Consumers) Rules, 2020 serve to “empower” citizens by laying down rights that make distribution companies more accountable to consumers. There are exceptions to these rules for certain categories, according to the Ministry of Power.
Adar Poonawalla: Need govt to indemnify vaccine makers against all lawsuits
According to Poonawalla, when “frivolous” claims crop up and are blown out of proportion, it affects the confidence of not just anti-vaxxers, but the general public too. Updated: December 20, 2020 9:00:53 pm
Serum Institute CEO Adar Poonawalla. (File Photo)
Vaccine makers need to be protected against liability for serious adverse reactions to their shots during a pandemic scenario, said Adar Poonawalla, Serum Institute of India (SII) CEO, on Friday.
The Pune-headquartered company plans to propose this to the government, he said during a virtual panel discussion on the challenges to vaccine development. This is because such issues could potentially increase fear against getting vaccinated and also works to “bankrupt” or “distract” the companies making them, according to him.
Explained: What is currency manipulation, and why has US put India on its currency watchlist?
The designation of a country as a currency manipulator does not immediately attract any penalties, but tends to dent the confidence about a country in the global financial markets. Written by Prabha Raghavan , Edited by Explained Desk | New Delhi | Updated: December 23, 2020 12:14:20 pm
Currency manipulation is when a country is artificially lowering the value of its currency to gain an unfair advantage over others. (Bloomberg Photo: Dhiraj Singh, File)
The United States has once again included India in its monitoring list of countries with potentially “questionable foreign exchange policies” and “currency manipulation”. This comes a year after India was removed from the watchlist in the US Treasury Department’s semi-annual foreign-exchange report to the US Congress.
Pune-based Gennova to begin human trials of its Covid vaccine ‘soon’ For phase 1, we have got two sites where we will be starting enrolment soon, he said, adding that around 120 volunteers will be registered in the first phase at two sites KEM Hospital, Pune and a government hospital in Kolhapur. Updated: December 15, 2020 8:19:38 am
Covid testing in New Delhi on Monday. (Express photo by Praveen Khanna)
Pune-based Gennova Biopharmaceuticals plans to kick off early- to mid-stage human trials of its Covid-19 vaccine candidate “soon”, enrolling around 620 participants across several sites over the next few months.
“We have started the processes. We hope to start phase 1 soon. We will present our phase 1 data to the DCGI (Drug Controller General of India), before starting the second phase, and so the timeline for the trials to be completed will depend on these factors,” said Gennova CEO Dr Sanjay Singh.